Prestige BioPharma Limited

KSE 950210.KS

Prestige BioPharma Limited Total Non-Current Liabilities for the year ending June 30, 2024: USD 36.46 M

Prestige BioPharma Limited Total Non-Current Liabilities is USD 36.46 M for the year ending June 30, 2024, a -20.25% change year over year. Total non-current liabilities are the sum of long-term debt and other non-current liabilities.

Prestige BioPharma Limited Total Non-Current Liabilities for the year ending June 30, 2023 was USD 45.72 M, a 110.61% change year over year.
Prestige BioPharma Limited Total Non-Current Liabilities for the year ending June 30, 2022 was USD 21.71 M, a 62.73% change year over year.
Prestige BioPharma Limited Total Non-Current Liabilities for the year ending June 30, 2021 was USD 13.34 M, a 16.28% change year over year.
Prestige BioPharma Limited Total Non-Current Liabilities for the year ending June 30, 2020 was USD 11.47 M, a 21.46% change year over year.

Key data

Date	Total Non-Current Liabilities	Shareholders' Equity	Other Liabilities	Total Liabilities

KSE: 950210.KS

Prestige BioPharma Limited

CEO	Ms. So-Yeon Park
IPO Date	Feb. 9, 2021
Location	Singapore
Headquarters	21 Biopolis Road
Employees	66
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Plastics Vaccines

Description

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research, development, and marketing of biosimilars and new antibody therapeutics in the Asia Pacific. The company primarily engages in the development of new and similar antibody drugs for solid tumor, pancreatic cancer, breast cancer, gastric cancer, and arthritis. It is also developing vaccines for COVID-19 virus. The company was incorporated in 2015 and is headquartered in Singapore.

Key trends

Past 5 years